Medications for Percutaneous Coronary Intervention

11 results

  • Argatroban (argatroban)

    (Argatroban)
    Gland Pharma Limited
    Usage: Argatroban Injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant for those with or at risk for HIT undergoing percutaneous coronary intervention (PCI).

  • Argatroban (argatroban)

    (Argatroban)
    Amneal Pharmaceuticals LLC
    Usage: Argatroban injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant in patients with HIT undergoing percutaneous coronary intervention (PCI).

  • Argatroban (argatroban)

    (Argatroban)
    Hikma Pharmaceuticals USA Inc.
    Usage: Argatroban Injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant for those undergoing percutaneous coronary intervention (PCI) who are at risk for HIT.

  • Bivalirudin (bivalirudin)

    (bivalirudin)
    Accord Healthcare, Inc.
    Usage: Bivalirudin for injection is indicated as an anticoagulant for patients undergoing percutaneous coronary intervention (PCI), including those with heparin-induced thrombocytopenia and thrombosis syndrome.

  • Eptifibatide (eptifibatide)

    (eptifibatide)
    Slate Run Pharmaceuticals, LLC
    Usage: Eptifibatide injection is indicated for decreasing the combined risk of death or new myocardial infarction in patients with Acute Coronary Syndrome (ACS) and for reducing death, new MI, or urgent intervention needs in patients undergoing Percutaneous Coronary Intervention (PCI), including stenting.

  • Eptifibatide (eptifibatide)

    (Eptifibatide)
    Hainan Shuangcheng Pharmaceuticals Co., Ltd.
    Usage: Eptifibatide injection is indicated for reducing the combined risk of death or new myocardial infarction in patients with acute coronary syndrome and for decreasing risks during percutaneous coronary interventions, including those receiving intracoronary stenting.

  • Eptifibatide (eptifibatide)

    (eptifibatide)
    Athenex Pharmaceutical Division, LLC.
    Usage: Eptifibatide injection is indicated for reducing the rates of death or new myocardial infarction in patients with acute coronary syndrome (ACS) and for decreasing the risk of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), including those receiving stents.

  • Eptifibatide (eptifibatide)

    (eptifibatide)
    Sagent Pharmaceuticals
    Usage: Eptifibatide Injection is indicated for the management of Acute Coronary Syndrome (ACS) to reduce the risk of death or new myocardial infarction. It is also used during Percutaneous Coronary Intervention (PCI) to lower the rates of death, new MI, or the need for urgent intervention.

  • Eptifibatide (eptifibatide)

    (eptifibatide)
    Mylan Institutional LLC
    Usage: Eptifibatide injection is indicated for reducing the risk of death or new myocardial infarction in patients with acute coronary syndrome (ACS) and for decreasing complications in patients undergoing percutaneous coronary intervention (PCI), including those receiving intracoronary stenting.

  • Eptifibatide (eptifibatide)

    (eptifibatide)
    Hainan Poly Pharm. Co., Ltd.
    Usage: Eptifibatide injection is indicated for reducing death or myocardial infarction rates in patients with acute coronary syndrome (ACS) and for decreasing death, new MI, or urgent intervention needs in patients undergoing percutaneous coronary intervention (PCI), including those with intracoronary stenting.